Clin Rheumatol. Zhang JM, An J. Cytokines, inflammation and pain. Int Anesthesiol Clin. J Immunol. Figiel I. Acta Neurobiol Exp Wars. Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.
Mediators Inflamm. Clark IA, Vissel B. Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents. J Neuroinflammation. Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Cheng F. State College: Pennsylvania State University; A new cytokine: the possible effect pathway of methionine enkephalin.
World J Gastroenterol. Zagon I, McLaughlin P. Opioid growth factor and the treatment of human pancreatic cancer: a review. Opioid growth factor receptor OGFR expression is downregulated with progression of triple negative breast cancer.
Int J Cancer Ther Oncol. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Enhancing acupuncture by low dose naltrexone. Acupunct Med. Increases in drug and opioid-involved overdose deaths — United States, — Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.
Arthritis Rheum. Furst DE, Emery P. Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology Oxford. Arthritis Res Ther. National Institutes of Health. US National Library of Medicine. Updated February 6, Low dose naltrexone for induction of remission in Crohn's disease. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study.
J Clin Gastroenterol. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World J Clin Cases. Wu GF, Alvarez E. The immuno-pathophysiology of multiple sclerosis. Neurol Clin.
Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Integr Cancer Ther. Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anticancer Drugs. Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer.
Open Access J Clin Trials. Gynecol Oncol. Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: implications for its use in cancer therapy. Int J Oncol. Risk for recurrence in depression. Clin Psychol Rev. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.
J Affect Disord. Pape W, Woller W. It must be preserved in tight containers. Naltrexone has little or no agonist activity, and its opioid antagonist activity is reported to be two to nine times that of naloxone and 17 times that of nalorphine.
It is a purified, partially depolymerized cellulose that occurs as a white, odorless, tasteless, crystalline powder that is composed of porous particles. Commercially, microcrystalline cellulose is available in different particle size ranges and moisture grades, with different properties and applications. Microcrystalline cellulose is listed as incompatible with strong oxidizing agents. A stable but hygroscopic material, microcrystalline cellulose should be stored in well-closed containers in a cool, dry place.
The use and utility of low-dose naltrexone capsules for patients with fibromyalgia. Compounded low-dose naltrexone for the treatment of guttate psoriasis: a case report. Sturn KM, Collins M. Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients.
Rockville, MD: U. Pharmacopeial Convention, Inc; February Allen LV Jr. Standard operating procedure for performing physical quality assessment of powder-filled, hard-gelatin capsules. Allen Jr LV. Summary of quality-control testing for sterile and nonsterile compounded preparations, part 1: physical and chemical testing.
Due to their hyposensitized opioidergic system, VLDN is a cautiously chosen dose of naltrexone with usual daily dose being either 0. In two randomized double blind studies [ 81 , 82 ], in which opioid-dependent patients were enrolled for a six-day methadone taper plus a placebo or VLDN, it was demonstrated that the active treatment, either 0. In a same-fashioned study design enrolling patients of whom 85 completed the trial, VLDN was compared to low-dose clonidine and placebo.
The VLDN-receiving group showed significantly less withdrawal symptoms compared to placebo and clonidine groups, respectively [ 83 ]. Likewise, an additional study with the repeated design and patients, which tracked smoking behavior as an extra outcome, concluded that VLDN eased withdrawal symptoms related to detoxification and in combination with low-dose clonidine significantly reduced craving for cigarettes [ 84 ]. A previous identically designed study run by the same group and for which opioid-dependent alcoholic patients were recruited [ 84 ], showed that VLDN significantly helped with withdrawal symptoms, adherence to treatment, and reducing alcohol intake, as reported per sixth day status post-detoxification completion.
In a different trial completed by 14 patients [ 85 ], VLDN was given in incremental fashion over a seven-day period with concurrent three-day buprenorphine taper in order to prepare subjects for administration of intramuscular extended release mg naltrexone.
As part of a detoxification treatment, VLDN was well tolerated throughout presented studies and there were no adverse effects reported that would otherwise be specifically linked to its. Due to limited follow-up information, it is impossible to determine the effects of VLDN for a period longer than one week. Vice-versa, patients without substance abuse history, but who are experiencing adverse effects with LDN, could possibly benefit from lower doses that would qualify as VLDN.
One of the first clinical reports on ULDN was when a patient suffering from terminal stage of cancer and severe intractable cholestasis pruritus, functionally improved upon introduction of 0. The ULDN infusion did not reduce her concurrent buprenorphine-based analgesia and even improved her mental condition impacted by high opioid dose [ 40 ]. In contrast to an impromptu use of ULDN, larger-scale clinical trials with an opioid and ULDN combination were conducted as continuous phases of drug development and translation of preclinical research mentioned earlier in Section 2.
The final analysis included patients. Patients receiving that combination reported significantly fewer opioid-related adverse effects such as constipation, somnolence, and pruritus.
The same group had the fewest percentage of patients affected by opioid-withdrawal effects following active treatment cessation. Unfortunately, a high dropout rate calls for serious caution when interpreting clinical significance of such an intervention [ 87 ]. The same research group ran a similar clinical trial assessing opioid in combination with ULDN for osteoarthritic pain.
Despite encouraging phase II results, there were high dropout rates in subsequent phase whereby no valid results could be obtained [ 88 ]. Both types of pain used in the studies might not have been the ideal to test the drug combination, as more recent evidence would not support the choice of opioid therapy in such cases [ 89 ].
There is some reliable data coming from surgical setting, where ULDN was added to bolster acute responses to opioids Table 4. A randomized placebo-controlled trial comprised of 80 patients who underwent lumbar discectomy procedure, assessed the effects of ULDN added to patient controlled postoperative analgesia [ 90 ]. Naloxone was given in a continuous infusion at a rate of 0. It was shown that the ULDN group had statistically significant faster pain relief and initially less reported nausea or pruritus, although both groups had very similar end-point values.
Median morphine consumption for the same group was 26 mg, whereas it was 34 mg in the placebo group. Another randomized double blind placebo-controlled trial examined the effects of ULDN given from the beginning of anesthesia until 72 h post open-colorectal surgery [ 91 ]. There were 72 patients who were allocated to sevoflurane anesthesia combined with lower dose remifentanil, higher dose remifentanil, or higher dose remifentanil with ULDN, respectively.
The analysis showed that the ULDN group of patients exhibited significantly faster bowel function recovery and a lower median hospital stay. Cumulative post-operative morphine use was similar in ULDN and lower dosed remifentanil groups, which significantly differed from a higher dosed remifentanil group, whose total post-operative opioid consumption was almost twice as high.
Onset of time for motor and sensory blockade were longer with additional ng of naloxone. Applying buprenorphine with naloxone in ratio boosts tolerance to cold pressor test. Adding 0. The clinical properties of ULDN were also tested for axillary brachial plexus blockade, where it was added to drugs used for regional anesthesia [ 92 ].
Groups receiving ULDN with or without fentanyl had a significantly and relevantly longer duration of motor and sensory block periods, though time of onset for these blocks was also prolonged for 5—7 min. Thereafter, postoperative pain appeared significantly later in ULDN groups. An interesting double-blind study assessed analgesic properties of buprenorphine combined with ULDN in various relative ratios , , , , respectively , by testing ten healthy subjects undergoing cold-pressor test [ 93 ].
Buprenorphine was given orally at a dose 0. All combinations provided an increase compared to baseline, but combination was statistically significant with most effective peak mean increase of It has shown promising efficacy in preclinical models.
Available pharmacological information describing the safety profile of naltrexone [ 9 ] reveal that except for precipitating withdrawal in opioid abuse the only major concern was hepatocellular injury ensuing from mg daily administered dose.
The usual daily 50— mg naltrexone therapy is considered fully safe for humans with minor behavioral side effects not entirely caused by the therapy itself, but rather due to the patient population having an underlying pathophysiological background of alcohol or opioid abuse.
Due to naloxone having poor oral bioavailability, systemic adverse effects following this route of administration are minimal. Improper parenteral administration could potentially lead to side effects [ 10 ], but in a real-case scenario the drug is usually administered under professional medical care.
In regard to LDN, data on actual side-effects linked to the drug is still scarce. Conducted clinical trials indicate that vivid dreaming and insomnia might occur following treatment initiation, but that this might be addressed by changing the drug taking timing from usual bedtime to morning hours or these sleep disturbances resolve on their own with ongoing therapy [ 14 , 44 ]. Any side-effects making the therapy intolerable might happen on individual basis, for example, a case of immune-related thrombocytopenia possibly related to LDN therapy as an idiosyncratic reaction in a patient affected by MS [ 95 ].
In the latter case, a precipitated opioid withdrawal could be managed by lowering the dose, as experience with VLDN demonstrates. In case of immunosuppression, for example, recipients of donor organs, it remains to be investigated if LDN-related immune modulation might cause adverse effects.
Proper clinical trials are needed in order to establish evidence that could lead to correct indications, mode of administration, and other aspects necessary for effective clinical pharmacology of LDN, VLDN, and ULDN.
Since these modalities possess a limited commercial attractiveness for industry, executing strongly designed studies is an arduous process.
Cancer research based on sound preclinical evidence regarding roles of LDN in opioid growth factor signaling might possibly be of specific public health interest. Based on current reports of numerous benefits and an excellent safety profile, clinical use of LDN may be seen as a reasonable option in patients with fibromyalgia or IBD.
In a hospital setting, ULDN could be investigated further as an additional option to increase postoperative analgesia or to reduce opioid-related side effects. New clinical applications are possible, given that LDN may be considered for sublingual, cream, or spray forms. Smart-drug design is also an option, for example, the case of PTI A recent review evaluating LDN in pain-related syndromes concluded that even though a potential exists, current evidence is limited [ 96 ].
National Center for Biotechnology Information , U. Journal List Med Sci Basel v. Med Sci Basel. Published online Sep Author information Article notes Copyright and License information Disclaimer. Received Aug 5; Accepted Sep This article has been cited by other articles in PMC. Abstract Naltrexone and naloxone are classical opioid antagonists. Introduction Naltrexone is classically prescribed in daily doses of at least 50 mg to be taken orally.
Aims and Purpose The primary scope of this narrative review is to present scientific evidence evaluating LDN as a treatment. Pharmacological Properties Naltrexone and naloxone are well-known opioid antagonists used in chronic or acute states of abuse [ 6 ], respectively. Mechanism of Action of Low-Dose Naltrexone The clinical phase of LDN pharmacological research preceded the bench-scientific one, thus theorizing on its exact mechanism of action has predominated until recently [ 12 ].
Mechanism of Action of Very Low-Dose Naltrexone There is no thorough pharmacological experimental study specifically evaluating pharmacodynamics of very low-dose naltrexone VLDN , besides some attempts in clinical setting discussed later in the article. Low-Dose Naltrexone in Clinical Medicine Low-dose naltrexone has been shown to ameliorate and modify the course of various diseases Table 1. Table 1 Mechanisms of action and clinical use in regard to different doses of naltrexone used.
Open in a separate window. Multiple Sclerosis The proposal for scientific investigation of LDN as a treatment for multiple sclerosis MS has been presented as a medical hypothesis in [ 45 ]. Table 2 A summary of clinical experience on low-dose naltrexone LDN in multiple sclerosis per peer-reviewed literature.
Complex Regional Pain Syndrome The name complex regional pain syndrome CRPS reflects features of this condition and its effective treatment is a clinical challenge. Fibromyalgia The first study evaluating LDN as an adjunct treatment in fibromyalgia was designed as single-blind placebo-crossover pilot and comprised ten women suffering from the condition [ 56 ].
Gastrointestinal Tract Diseases The first application of LDN in gastrointestinal-related issues was in , when an Israeli research group presented a pilot study involving 42 patients suffering from irritable bowel syndrome IBS [ 59 ].
Cancer The initial findings showing lower dosed naltrexone reduced the size of an experimentally implanted neuroblastoma tumor, whereas a higher dosed naltrexone produced exact opposite effects [ 66 ], opened the perspective of opioid-immune interactions and cancer growth, particularly concerning mechanisms involving low-dose naltrexone and opioid growth factor receptor signaling for a recent topical review see [ 33 ].
Skin Conditions Two recently published case reports describe significant amelioration of the skin condition known as Hailey-Hailey disease after LDN has been used as a sole treatment [ 71 , 72 ]. Other Diseases or States The first published randomized controlled trial on LDN was provided by a team of psychiatrists. Ultra Low-Dose Naltrexone in Clinical Medicine One of the first clinical reports on ULDN was when a patient suffering from terminal stage of cancer and severe intractable cholestasis pruritus, functionally improved upon introduction of 0.
Safety and Side Effects Available pharmacological information describing the safety profile of naltrexone [ 9 ] reveal that except for precipitating withdrawal in opioid abuse the only major concern was hepatocellular injury ensuing from mg daily administered dose. Author Contributions Both authors contributed equally to this article. Funding This research received no external funding. Conflicts of Interest The authors declare no conflict of interest. References 1. Sudakin D. Naltrexone: Not Just for Opioids Anymore.
Bihari B. Low-dose naltrexone for normalizing immune system function. Health Med. CFS Pharmacy Shop Raknes G. A sudden and unprecedented increase in low dose naltrexone LDN prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study. Drug Saf. Schumacher M. In: Katzung B. Burns L. Ultra-low-dose naloxone or naltrexone to improve opioid analgesia: The history, the mystery and a novel approach.
Insights Ther. Wang X. Alcohol Pharmacother. Into Med. Treatment Improv. Hospira Inc. Naloxone Prescribing Information Robinson A. Intranasal naloxone administration for treatment of opioid overdose.
Brown N. Low-dose naltrexone for disease prevention and quality of life. Calabrese E. Hormetic mechanisms. Younger J. The use of low-dose naltrexone LDN as a novel anti-inflammatory treatment for chronic pain.
Agarwal D. Therapeutic value of naltrexone as a glial modulator. Selfridge B. Hutchinson M. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 TLR4 Eur. Okun E. Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci. Wadachi R. Leow-Dyke S. Neuronal toll-like receptor 4 signaling induces brain endothelial activation and neutrophil transmigration in vitro.
Lehnardt S. Innate immunity and neuroinflammation in the CNS: The role of microglia in toll-like receptor-mediated neuronal injury. Chopra P. Neuroimmune Pharmacol. Enkephalins, brain and immunity: Modulation of immune responses by methionine-enkephalin injected into the cerebral cavity.
Rahn K. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone LDN or opioid growth factor OGF for an extended period: Therapeutic implications for multiple sclerosis. Brain Res. McCusker R. Yoburn B. Opioid antagonist-induced receptor upregulation: Effects of concurrent agonist administration. The effect of CRH, dexamethasone and naltrexone on the mu, delta and kappa opioid receptor agonist binding in lamb hypothalamic-pituitary-adrenal axis.
Folia Biol. Zukin R. Naltrexone-induced opiate receptor supersensitivity. Tempel A. Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation. Zagon I. Targeting the opioid growth factor: Opioid growth factor receptor axis for treatment of human ovarian cancer.
Maywood ; — Rogosnitzky M. Opioid growth factor OGF for hepatoblastoma: A novel non-toxic treatment. New Drugs. Donahue R. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: Mechanistic evidence from a tissue culture model.
McLaughlin P. Duration of opioid receptor blockade determines biotherapeutic response. Lutz P. Opioid receptors: Distinct roles in mood disorders. Shen K. Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture. Wang H. Recent Pat. CNS Drug Discov. Smith J. Berkson B. Reversal of signs and symptoms of a B-cell lymphoma in a patient using only low-dose naltrexone.
Cancer Ther. Zylicz Z.
0コメント